Ukr.Biochem.J. 2020; Volume 92, Issue 6, Nov-Dec, pp. 137-142

doi: https://doi.org/10.15407/ubj92.06.137

Indicators of lipid metabolism disorders in the blood serum of adolescents with metabolic syndrome

17.12.2020   Uncategorized   No comments

L. A. Strashok1,2, O. V. Buznytska1,2*, О. М. Meshkova3

1Kharkіv Medical Academy of Postgraduate Education, Ukraine;
2V.N. Karazin Kharkіv National University, Ukraine;
3Bogomolets National Medical University, Kyiv, Ukraine;
*e-mail: ebuznickaa@ukr.net; elena.buznytska@gmail.com

Received: 16 April 2018; Accepted:13 November 2020

Atherogenic dyslipidemia is one of the main and early indication of adolescentrs with metabolic syndrome. Because there is not enough information about the nature of dyslipidemia in adolescents and the possibilities of its correction and prevention, the study of this problem is relevant. The goal of the study was to estimate the indexes of lipid metabolism in blood serum of adolescents with metabolic syndrome. We examined 200 obese patients aged 14–18 years, who were divided into two groups with and without metabolic syndrome. The control group consisted of 30 adolescents of similar age with normal body weight. The lipid profile of blood was studied by standardized methods using Cormay Multi semi-automatic photometer­. The level of β-lipoproteins in blood serum was determined by the turbidimetric method. Elevated levels of triglycerides, low and very low density lipoprotein cholesterol, β-lipoproteins and a tendency to decreased high density lipoprotein level cholesterol were found in the  blood serum of adolescents with metabolic syndrome  as the signs of atherogenic dyslipidemia. Reliable correlations both between the indexes of lipid profile and between atherogenic dyslipidemia indicators and anthropometric indexes were established, indicating an increased risk of lipid metabolic disturbances in individuals with abdominal obesity.

Keywords: , ,

References:

  1. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, Wong G, Bennett P, Shaw J, Caprio S, IDF Consensus Group. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes. 2007;8(5):299-306. PubMed, PubMedCentral, CrossRef
  2. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1-12. PubMed, CrossRef
  3. Gromnatska N, Cherkas A, Lemishko B, Kulya O. The pattern of metabolic syndrome in children with abdominal obesity. Georgian Med News. 2019;(289):68-72. PubMed
  4. Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl Pediatr. 2017;6(4):397-407. PubMed, PubMedCentral, CrossRef
  5. Tagi VM, Giannini C, Chiarelli F. Insulin Resistance in Children. Front Endocrinol (Lausanne). 2019;10:342. PubMed, PubMedCentral, CrossRef
  6. McCrindle BW. Summary of the American Heart Association’s scientific statement on drug therapy of high-risk lipid abnormalities in children and adolescents. Arterioscler Thromb Vasc Biol. 2007;27(5):982-985.   PubMed, CrossRef
  7. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18(Suppl 1):1-78. PubMed, CrossRef
  8. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113(25):2943-2946. PubMed, CrossRef
  9. Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971;75(3):471-472. PubMed, CrossRef
  10. Barclay L, Desiree L. Waist-to-height ratio may predict cardiometabolic risk in normal-weiht children CME. BMC Pediatr. 2010; 10: 73-78.
  11. Heinonen OP, Huttunen JK, Manninen V, Mänttär M, Koskinen P, Tenkanen L, Frick MH. The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up. J Intern Med. 1994;235(1):41-49.  PubMed, CrossRef
  12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. PubMed, CrossRef
  13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107(6):811-826. PubMed, CrossRef
  14. Kawada T. Socioeconomic status and childhood metabolic syndrome. Int J Cardiol. 2019;283:189. PubMed, CrossRef
  15. Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51(4):305-312. PubMed, PubMedCentral, CrossRef
  16. Spreghini N, Cianfarani S, Spreghini MR, Brufani C, Morino GS, Inzaghi E, Convertino A, Fintini D, Manco M. Oral glucose effectiveness and metabolic risk in obese children and adolescents. Acta Diabetol. 2019;56(8):955-962. PubMed, CrossRef
  17. Troisi J, Belmonte F, Bisogno A, Lausi O, Marciano F, Cavallo P, Nuzio SG, Landolfi A , Pierri L, Vajro P. Salivary markers of hepato-metabolic comorbidities in pediatric obesity. Dig Liver Dis. 2019;51(4):516-523. PubMed, CrossRef
  18. Fang Y, Ma Y, Mo D, Zhang S, Xiang M, Zhang Z. Methodology of an exercise intervention program using social incentives and gamification for obese children. BMC Public Health. 2019;19(1):686. PubMed, PubMedCentral, CrossRef
  19. Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64-76. PubMed,  CrossRef
  20. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349-360. PubMed, PubMedCentral, CrossRef
  21. Seo SH, Shim YS. Association of Sleep Duration with Obesity and Cardiometabolic Risk Factors in Children and Adolescents: A Population-Based Study. Sci Rep. 2019;9(1):9463. PubMed, PubMedCentral, CrossRef
  22. Buznytska OV. Diagnostic significance of biochemical indicators of liver fibrogenesis in adolescents with obesity. Ukr Biochem J. 2019;91(1):74-79. CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.